CYCLERION THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
CYCLERION THERAPEUTICS, INC. (CYCN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.79% for the 12-month period ending 2025-12-31, per its S-4/A filed 2026-07-22.
Financial Statements › Notes › Compensation Related Costs › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-07-22
- CYCLERION THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.47%, a 79.79% increase from fiscal 2022.
- CYCLERION THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.93%, a 77.06% increase from fiscal 2021.
- CYCLERION THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 1.09%, a 153.49% increase from fiscal 2020.
- CYCLERION THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 0.43%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|
| 2025-12-31 | 3.79% S-4/A · filed 2026-07-22 |
| 2024-12-31 | 3.64% S-4/A · filed 2026-07-22 |
| 2023-12-31 | 3.47% 10-K/A · filed 2025-11-12 |
| 2022-12-31 | 1.93% 10-K · filed 2024-03-05 |
| 2021-12-31 | 1.09% 10-K · filed 2023-03-22 |
| 2020-12-31 | 0.43% 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |